Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006)

Journal:
Nature Communications
Published:
Affiliations:
6
Authors:
10
Institutions Authors Share
Hunan Provincial People's Hospital, China
3.333333
0.33
Hubei Cancer Hospital (HBCH), China
2.000000
0.20
Jiangxi Provincial Cancer Hospital, China
2.000000
0.20
Fujian Provincial Hospital, China
2.000000
0.20
Hunan Cancer Hospital, China
0.333333
0.03
Central South University (CSU), China
0.333333
0.03